Teva launches generic Aggrenox in United States

JERUSALEM — Teva Pharmaceuticals announced the U.S.-wide availability of generic Aggrenox (aspirin and extended-release dipyridamole) capsules, which contain that can reduce the risk of stroke, on Wednesday.

“Teva recognizes the devastating impact of a stroke and is pleased to launch generic aspirin and extended-release dipyridamole capsules as a treatment option for at-risk stroke patients,” Brendan O’Grady, Teva’s president and CEO of North America Generic Medicines, said.

The National Institutes of Health estimates 185,000 Americans are at risk of another stroke within five years of a previous stroke. Every year, more than 795,000 Americans have a stroke, and 25% have had a previous stroke.